Chardan Capital Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX)

Chardan Capital reiterated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX - Free Report) in a report published on Friday morning,Benzinga reports. They currently have a $6.00 price objective on the stock.

Several other brokerages have also recently issued reports on GANX. Roth Mkm reissued a "buy" rating and issued a $7.00 price objective on shares of Gain Therapeutics in a report on Tuesday, December 24th. Roth Capital raised Gain Therapeutics to a "strong-buy" rating in a report on Thursday, December 5th. Scotiabank assumed coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $12.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, March 17th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $8.20.

Gain Therapeutics Stock Performance

NASDAQ GANX traded down $0.09 during trading hours on Friday, reaching $1.82. The stock had a trading volume of 112,001 shares, compared to its average volume of 281,121. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.04. The stock has a fifty day moving average of $2.21 and a 200 day moving average of $2.07. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The stock has a market cap of $48.28 million, a P/E ratio of -1.66 and a beta of 0.14.

Remove Ads

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07. Sell-side analysts predict that Gain Therapeutics will post -1 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp lifted its holdings in Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company's stock valued at $212,000 after purchasing an additional 44,750 shares in the last quarter. Geode Capital Management LLC increased its stake in Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company's stock worth $484,000 after buying an additional 88,236 shares in the last quarter. Benedict Financial Advisors Inc. acquired a new position in shares of Gain Therapeutics during the fourth quarter valued at approximately $35,000. Sprott Inc. purchased a new position in shares of Gain Therapeutics in the fourth quarter valued at approximately $30,000. Finally, Northern Trust Corp boosted its stake in shares of Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock worth $183,000 after acquiring an additional 39,642 shares during the last quarter. Hedge funds and other institutional investors own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.